Trial · NCT07899788
CATCH AF - Atrial Fibrillation Detection in Cryptogenic Stroke
NCT07899788, Not applicable, Not yet recruiting, Medical University of Graz
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. CATCH AF - Atrial Fibrillation Detection in Cryptogenic Stroke. Trials, record NCT07899788. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07899788
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- CATCH AF - Atrial Fibrillation Detection in Cryptogenic Stroke
- NCT number
- NCT07899788
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 1,500 participants, estimated
- Lead sponsor
- Medical University of Graz
- Conditions
- Atrial Fibrillation (AF)
- Interventions
- CardioWatch 287-2 Group, Control Group
- First posted
- 2026-10-28
- Last updated
- 2026-10-29
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Occurrence of atrial fibrillation detected after stroke (AFDAS) within 3 months post-stroke | 3 months post-stroke | Proportion of participants with AFDAS detected within 3 months after the index stroke. Define AFDAS according to the study protocol. Unit of Measure: Participants / % |
| Secondary | Occurrence of AFDAS within 12 months post-stroke | 12 months after index stroke | Proportion of participants with AFDAS detected within 12 months after the index stroke. Unit of Measure: Participants / % |
| Secondary | Time to first AFDAS detection | Up to 12 months after index stroke | Time from the index stroke to first documented detection of AFDAS. Unit of measure: Days |
| Secondary | Time to initiation of direct oral anticoagulant (DOAC) therapy | Up to 12 months after index stroke | Time from the index stroke to initiation of DOAC therapy. Specify the analysis population according to the protocol. Unit of measure: Days |
| Secondary | Occurrence of recurrent ischemic stroke within 3 months post-stroke | 3 months after the index stroke | Proportion of participants experiencing recurrent ischemic stroke within 3 months after the index stroke. Unit of measure: Participants / % |
| Secondary | Occurrence of myocardial infarction within 3 months post-stroke | 3 months after the index stroke | Proportion of participants experiencing myocardial infarction within 3 months after the index stroke. Unit of measure: Participants / % |
| Secondary | Occurrence of acute peripheral arterial occlusion within 3 months post-stroke | 3 months after the index stroke | Proportion of participants experiencing acute peripheral arterial occlusion within 3 months after the index stroke. Unit of measure: Participants / % |
| Secondary | Occurrence of recurrent ischemic stroke within 12 months post-stroke | 12 months after the index stroke | Proportion of participants experiencing recurrent ischemic stroke within 12 months after the index stroke. Unit of measure: Participants / % |
| Secondary | Occurrence of myocardial infarction within 12 months post-stroke | 12 months after the index stroke | Proportion of participants experiencing myocardial infarction within 12 months after the index stroke. Unit of measure: Participants / % |
| Secondary | Occurrence of acute peripheral arterial occlusion within 12 months post-stroke | 12 months after the index stroke | Proportion of participants experiencing acute peripheral arterial occlusion within 12 months after the index stroke. Unit of measure: |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers8
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07899788
GET https://conductscience.org/api/trials/v1/NCT07899788/registered